Navigation Links
ScinoPharm Granted US Patent for Novel Crystal Forms

TAINAN, Taiwan, Nov. 25 /PRNewswire-Asia/ -- ScinoPharm, an active pharmaceutical ingredient (API) specialist, announced it has been granted US Patent No. 7,435,818 entitled "Novel Crystal Forms of Irinotecan Hydrochloride." The new patent provides for novel crystalline forms of irinotecan hydrochloride and processes for their preparation as well as pharmaceutical compositions containing the new forms and methods of treating metastatic carcinoma of the colon or rectum using these new forms.

This patent is the ninth US patent granted to ScinoPharm and the second patent for one of the company's high demand oncology products, irinotecan hydrochloride. ScinoPharm has already been granted a US Patent No. 7,157,179 covering the proprietary process for the preparation of a key intermediate of irinotecan hydrochloride.

The present invention provides crystalline forms of irinotecan hydrochloride that are more easily filtered from solution as compared to the existing forms of irinotecan hydrochloride. This increased ease of filtering promotes more efficient handling and processing of irinotecan hydrochloride during the manufacturing process, thus facilitating the formulation of new and improved pharmaceutical compositions which contain irinotecan hydrochloride.

"That we were awarded a US patent while other patent applications for the same polymorph are still pending in many other countries demonstrates our competence in the development and manufacture of oncological drug substances," stated Dr. Hardy Chan, CSO and Executive Vice President of ScinoPharm.

"And yet again we solidify our position as the world's leading supplier of irinotecan hydrochloride to the generic industry with adequate patent protection and continuous commitment to innovation," Dr. Chan added.

The latest patent adds to ScinoPharm's growing patent portfolio which now consists of 11 granted patents and more than 24 patent applications in the United States and abroad for a wide range of products.

Irinotecan hydrochloride, a cancer drug most commonly used to treat patients with metastatic carcinoma of the colon or rectum, became generic in the US in February 2008. Annual sales of the drug in the US market alone were approximately US$556 million in 2007, according to IMS Health data.

To provide broad access to markets worldwide, ScinoPharm has registered a Drug Master File (DMF) for irinotecan hydrochloride in 40 countries, including the United States and most European countries.

Specializing in the development and manufacture of highly potent compounds with proprietary processes, ScinoPharm is among the leading companies supplying oncological API. In addition to irinotecan hydrochloride, ScinoPharm offers 20 other products in its oncological line, including paclitaxel and docetaxel.

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd. is a leading high quality API supplier to the global pharmaceutical and biotechnology industry. We provide a full range of API services from process development, and production of early phase clinical trial material to large-scale manufacturing for commercial launches. The company currently serves more than 190 customers worldwide. For more information, please visit the company's web site at .

    Media Contact:

    ScinoPharm Taiwan, Ltd.
    Jessie Wang
    Tel:   +886-6-505-2888

SOURCE ScinoPharm Taiwan, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
2. MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process
3. Autonomy(TM) Lapro-Angle(TM) Articulating Laparoscopic Instruments Granted CE Mark
4. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
5. Biopure Granted Additional 180 Day Compliance Period by NASDAQ
6. Skinvisible Patent Granted in Australia
7. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
8. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
9. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
10. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
11. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
Post Your Comments:
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") ( ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):